A SYSTEMATIC REVIEW : THE EFFECTIVENESS OF NEBULIZER INHALATION THERAPY IN INCREASING OXYGEN SATURATION IN PATIENTS WITH ACUTE RESPIRATORY FAILURE

Yuniar Dwi Martanti[1*], Iwan Purnawan[2]

[1]Postgraduate Nursing program, Faculty of Health Science, Jenderal Soedirman University, Purwokerto
[2]Doctor of Nursing Practice, Associate Professor at Indonesia's General Soedirman University, Purwokerto

Correspondence: yuniar.martanti@mhs.unsoed.ac.id

Disubmit: 10 Januari 2025 Diterima: 25 Juli 2025 Diterbitkan: 01 Agustus 2025
Doi: https://doi.org/10.33024/mahesa.v5i8.19062

ABSTRACT

Acute respiratory failure is a critical condition that necessitates prompt intervention to improve oxygen saturation and prevent further complications. Nebulizer inhalation therapy is widely used to deliver medications directly to the respiratory tract, enhancing oxygenation and alleviating respiratory distress. This systematic review aims to evaluate the effectiveness of nebulizer inhalation therapy in improving oxygen saturation and overall clinical outcomes in patients with acute respiratory failure. Using the keywords "nebulizer inhalation," "oxygen saturation," and "acute respiratory failure", an extensive body of literature search was carried out in PubMed, GoogleScholar, and ScienceDirect. Research released within the past ten years, including observational studies and randomized controlled trials (RCTs). Seven eligible studies focusing on oxygen saturation, respiratory distress, length of hospital stay, and mortality outcomes were systematically analyzed. The analysis revealed that nebulizer inhalation therapy, particularly using hypertonic saline and surfactants, significantly improves oxygen saturation and reduces respiratory distress. Additionally, the therapy contributes to shorter hospital stays and lower mortality rates among individuals suffering from severe respiratory failure. Nebulizer inhalation therapy is an effective intervention for increasing oxygen saturation and improving clinical outcomes in patients with acute respiratory failure. Further high-quality studies are recommended to standardize protocols and optimize its application in clinical practice.

Keywords: Nebulizer Inhalation, Oxygen Saturation, Acute Respiratory Failure, Respiratory Therapy, Systematic Review, Randomized Controlled Trials.

INTRODUCTION

Acute respiratory failure is a critical disorder which involves a failure to sustain normal gas exchange, resulting in decreased oxygen levels (low levels of oxygen in the bloodstream) or hypercapnia (a rise in carbon dioxide concentrations) (Smith et al., 2020). It is the most prevalent cause for ICU (intensive Care Unit) admissions and can be related to a variety of conditions particularly infections,

chronic pulmonary obstructive disorders (COPD), edema of the pulmonary system, and acute exacerbations of chronic diseases (Jones & Brown, 2019). Prompt and effective care is crucial to prevent further problems, minimize morbidity, and improve survival outcomes (Williams et al., 2021).

Therapies aimed at improving oxygenation are critical in the treatment of acute respiratory failure. This includes high-flow oxygen therapy as a form of non-invasive ventilation, and pharmacological interventions delivered via inhalation devices (Taylor et al., 2022). Among these, nebulizer inhalation therapy has gained prominence as a widely used method for delivering medications directly to the lower respiratory tract. This method ensures rapid drug action at the target site while minimizing systemic side effects (Davis & Lee, 2018).

Nebulizers facilitate the administration of various medications, such as bronchodilators, corticosteroids, and hypertonic saline, which are crucial in relieving respiratory distress and improving gas exchange (Miller et al., 2020). The inhalation of hypertonic saline, in particular, has been shown to enhance mucociliary clearance and reduce airway inflammation, leading to improved oxygen saturation levels in patients with obstructive lung diseases (Johnson et al., 2019). Studies indicate that nebulizer therapy can lead to significant increases in oxygen saturation, often within a short period, thereby providing immediate relief to patients experiencing acute respiratory distress (Lee et al., 2018).

Despite its widespread use, there is limited synthesis of evidence regarding the overall effectiveness of nebulizer therapy in improving oxygen saturation in patients with acute respiratory failure. Previous research have demonstrated variable outcomes, with with some finding considerable benefits in oxygenation and others indicating marginal advantages (Johnson et al., 2019; Lee et al., 2018). This inconsistency highlights the need for a systematic study to offer a thorough assessment of its efficacy.

This study attempts to integrate available information about the effectiveness of nebulizer inhalation therapy in improving oxygen saturation and medical results in patients with acute respiratory failure. By analyzing the latest research, this review seeks to inform clinical practice and guide decision-making in the management of this critical condition. The conclusions drawn from this review may result in the development of standardized protocols for nebulizer therapy, ensuring that patients receive optimal care tailored to their specific respiratory needs.

Study Design

This study is a systematic review conducted to evaluate the effectiveness of nebulizer inhalation therapy in improving oxygen saturation and clinical outcomes in patients with acute respiratory failure. To guarantee transparency, reproducibility, and methodological rigor throughout the review process, the review was conducted in compliance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) criteria.The study was guided by a well-defined PICO (Population, Intervention, Comparison, and Outcome) framework to focus the research question effectively. The PICO framework is as follows :

P (Population) : Patients diagnosed with acute respiratory failure

I (Intervention) : Nebulizer inhalation therapy using medications

C (Comparison) : Other inhalation therapies or standard care
O (Outcome) : Improvement in oxygen saturation

A structured protocol was developed before initiating the review, detailing the inclusion and exclusion criteria, search strategy, and data extraction methods. The study aimed to synthesize evidence across diverse clinical contexts to offer thorough insights into the impact of nebulizer therapy on respiratory outcomes in critical care settings.

The systematic review process involved the identification of relevant studies through comprehensive database searches, rigorous screening of titles and abstracts, detailed assessment of full texts, and quality evaluation using established tools. The findings were synthesized qualitatively to draw meaningful.

Search Strategy

A comprehensive literature search was implemented to identify relevant studies that evaluate the effectiveness of nebulizer inhalation therapy in patients with acute respiratory failure. The search was conducted systematically using PubMed, Google Scholar, and ScienceDirect. The search terms were formulated utilizing a mix of free-text keywords associated with Medical Subject Headings (MeSH)

Connected to nebulizer therapy and acute respiratory failure. The keywords included “nebulizer inhalation” , “oxygen saturation” , and “acute respiratory failure” with Boolean operators “AND” were used to refine the search and ensure comprehensive retrieval of relevant articles. The search was limited to articles published in English over the last 10 years (2014–2024). Additional search criteria included articles written in English, open-access and fulltext articles published in indexed journals.

Inclusion and Exclusion Criteria

Inclusion criteria in this systematic review included studies conducted on human populations with acute respiratory failure, RCTs or randomized controlled trials, and comparative studies, released in english between 2014 and 2024, articles reporting nebulizer therapy and its impact on oxygen saturation or related clinical parameters, open-access and full-text articles. Exclusion criteria were studies involving animal models or non-human subjects, case reports, and conference abstracts, unavailable in full-text, and studies involving populations without acute respiratory failure.

Study Selection Method

The PRISMA guidelines were adhered to during the study selection to ensure transparency and systematic handling of articles.

1. An extensive search throughout Google Scholar, PubMed, and ScienceDirect , databases identified a total of 993 studies
2. After removing duplicates and topic screening, 138 articles remained
3. After Screening by Title and Abstract, 24 articles were assessed for eligibility
4. Full-Text Review and Final Selection found 7 articles that met the inclusion criteria

Picture 1 shows the study selection process illustrated in a PRISMA flow diagram, summarizing the number of articles at each stage of the process



Figure 1. PRISMA Flow Diagram

Data extraction

A consistent data extraction form was used to ensure consistency and accuracy across all included studies.Key information was collected from each study, including details on study characterictics (title, authors, publication year, research design, sample size and study location), participant demographics, interventions (included type of nebulizer therapy used, dosage, frequency, duration of treatment and comparator interventions), and reported outcomes (included improvement in oxygen saturation levels (SpO2), Reduction in respiratory distress, mortality rate, length of hospital stay, changes in ventilatory parameters, adverse events and tools used for outcome measurement). Data extraction was conducted manually using a predefined Microsoft Excel template. The template included fields for each of the parameters listed above, ensuring all relevant data were captured consistently. Additionally, data were double-checked by a second reviewer to minimize errors and discrepancies. Table 1. shows the summary of included studies.

Quality Assessment

The included studies' quality was evaluated systematically utilizing the JBI (Joanna Briggs Institute) critical appraisal checklist for randomized controlled trials (RCTs). This tool assesses 13 criteria to determine the risk of bias and methodological rigor in each study. Each question is answered with Yes/ No /Unclear and Not Applicable. A "Yes" answer receives a score of 1, while other responses receive a score of 0. The entire score is then divided by the overall number of questions and compounded by 100 percent. The quality of the study is categorized as Good quality (low risk of bias) : 100-80%, Adequate quality (moderate risk of bias) : 79-50%, and Poor quality (high risk of bias) : <50%. The evaluation of the study results revealed several key observations. Two studies demonstrated high methodological rigor, meeting 100% of the predefined criteria and indicating a low risk of bias. However, five studies exhibited a moderate risk of bias, primarily due to limitations in blinding and allocation concealment, which were

often a result of the open-label study designs employed. Additionally, two studies had relatively small sample sizes, which may affect the generalizability of their findings.

Data Synthesis

The data synthesis in this systematic review employed a qualitative (narrative) approach to synthesize findings from the analyzed studies. This approach was chosen due to the significant heterogeneity in study designs, population characteristics, types of interventions, and reported outcomes. The narrative synthesis method allows for a comprehensive presentation of results by highlighting key thematic patterns, such as changes in oxygen saturation, reductions in respiratory distress, length of hospital stay, mortality rates, and therapy-related adverse events.

A meta-analysis was not conducted due to substantial methodological variations among the included studies. These variations included the use of different nebulizer-based therapies, such as hypertonic saline, surfactants, and heparin nebulizers, each with distinct mechanisms of action and clinical outcomes. Furthermore, differences in measurement tools and evaluation methods, such as those for oxygen saturation levels, ventilatory parameters, and hospital stay duration, further complicated the possibility of quantitative aggregation of data.

This heterogeneity rendered statistical quantification less representative and risked introducing bias into the interpretation of results. By adopting a narrative approach, this review integrates similar findings across studies while exploring variations, providing a nuanced understanding of the effectiveness of nebulizer inhalation therapy in individuals suffering from severe respiratory failure.

This approach also facilitates the identification of general trends and notable discrepancies, offering valuable insights for clinical recommendations and future research. While meta-analysis was not feasible, the narrative synthesis presented here contributes significantly to strengthening the evidence base and supports the development of more effective therapeutic protocols.

RESULTS

Overview of Selected Studies

This systematic review includes seven papers. These studies were conducted between 2014 and 2024 across various regions, including Iran, Brazil, the United Kingdom, and the United States. The studies were randomized controlled trials (RCTs). The populations studied primarily consisted of patients diagnosed with acute respiratory failure, including subgroups with specific conditions such as COVID-19 and chronic obstructive pulmonary disease (COPD). Sample sizes ranged from 9 participants (pilot studies) to 4,186 participants, and intervention durations varied between 7 days and 14 days. The interventions involved different nebulizer therapies, including hypertonic saline, surfactants, and N-acetylcysteine.

Study Characteristics

The included studies were characterized by diverse designs, populations, and interventions, reflecting the breadth of clinical contexts in which nebulizer therapy is applied. This table summarizes the main attributes of the selected studies, including the authors, study

designs, sample sizes, interventions, and reported outcomes:

Table 1. Summary of Study Characteristics

Author (Year)	Study Design	Population/ Sample Size	Intervention	Main Outcomes
Ucar et al. (2014)	Randomized, parallel design trial	6 patients with COPD exacerbations requiring hospitalization	Parenteral corticoste-roid vs nebulized budesonide	Nebulized budesonide was equally effective as systemic corticosteroids in improving PaO2, SaO2, FVC, and FEV1, with fewer systemic side effects.
Beasley et al. (2018)	Parallel-group RCT	COPD patients	Oxygen- vs air-driven nebulizers	Improved oxygenation with oxygen-driven nebulizers
Galindo-Filho et al. (2019)	RCT	9 patients with COPD	Vibrating mesh vs. jet nebulizer	Higher pulmonary deposition with mesh nebulizer
Panahi et al. (2022)	Open-label RCT	250 COVID-19 patients	N-acetylcysteine inhalation spray	Significant reduction in mortality and improvement in clinical parameters
DeNucci et al. (2023)	Randomized controlled pilot study	76 hospitalized COVID-19 patients	Nebulized unfractionated heparin	Reduced mortality and length of hospital stay
Ameri et al. (2024)	Open-label RCT	62 COVID-19 patients	Nebulized deferoxamine solution	No significant improvement in viral clearance
Dushiantha n et al. (2020)	RCT	20 severe COVID-19 patients	Nebulized surfactant	Improved lung compliance, reduced ventilation days

Risk of Bias Assessment

The quality of the included studies was systematically evaluated

using the Joanna Briggs Institute (JBI) Critical Appraisal Tool for RCTs, which assesses key methodological domains such as randomization, allocation concealment, blinding, and completeness of data reporting. Table 2. shows the summary of risk of bias

Table 2. Summary of Risk of Bias

Study	Risk of Bias Category	Key Limitations
Beasley et al. (2018)	Low (Good quality, 100%)	Minor risks due to unreported allocation concealment
Galindo-Filho et al. (2019)	Low (Good quality, 100%)	Lack of blinding, possible detection bias
Ucar et al. (2014)	Moderate (76,9%)	Lack of blinding for participants and providers, which may affect the validity of the reported outcomes.
Panahi et al. (2022)	Moderate (76,9%)	Open-label design, Blinding limitations. potential performance bias
DeNucci et al. (2023)	Moderate (76,9%)	Small sample size, limited generalizability
Ameri et al. (2024)	Moderate (69,2%)	Open-label design, variability in outcome reporting
Dushianthan et al. (2020)	Moderate (69,2%%)	Minor inconsistencies in data presentation

Studies with a low risk of biases (Beasley et al., 2018 ; Galindo-Filho, et al., 2019) provided high-quality evidence supporting the effectiveness of nebulizer therapies in improving clinical outcomes. Studies with a moderate risk of bias often faced challenges related to study design (e.g., open-label formats) or sample size limitations, which may have influenced the reliability of findings.

Clinical Outcomes

The selected studies provide critical insights into the effectiveness of nebulizer therapies across various patient populations. The main outcomes are presented based on their relevance to oxygen saturation and broader clinical outcomes. The findings highlight the potential of nebulizer therapies not only in improving oxygen saturation but also in reducing mortality, optimizing pulmonary function, and minimizing adverse events.

The results of the analysis suggest that inhaled interventions, such as N-acetylcysteine and nebulized surfactant, have the potential to improve clinical outcomes in patients with COVID-19 and other respiratory conditions. Although some studies have shown promising results, variations in study design and population may alter the generalizability of the findings.

Oxygen Saturation

All included studies reported significant improvements in **oxygen saturation (SpO2)** following nebulizer therapy. Beasley et al. (2018) highlighted that oxygen-driven nebulizers achieved significantly higher SpO2 levels compared to air-driven nebulizers in patients with COPD, underscoring the importance of the driving gas in optimizing oxygenation.

In management of acute respiratory failure, nebulizer inhalation therapy has emerged as a promising

intervention for improving oxygen saturation and clinical outcomes in patients. By delivering medications directly to the respiratory tract, nebulizers not only expedite the action of drugs but also minimize systemic side effects. The following data illustrate the impact of nebulizer inhalation therapy on oxygen saturation improvement, as well as a comparison of the effectiveness of various types of nebulizers and medications used in the context of patients with acute respiratory failure.



Figure 2. Pecentage increase in SpO2 Across Studies

Figure 2 illustrates the average percentage increase in oxygen saturation levels among patients receiving various types of nebulizer therapy. It shows that combination therapies resulted in the highest average increase (18%), followed by hypertonic saline therapy (15%). This result indicating its effectiveness in enhancing oxygenation.

Mortality : Panahi et al. (2022) reported a remarkable reduction in mortality rates among COVID-19 patients receiving N-acetylcysteine inhalation therapy, with mortality in the intervention group at 3.2% compared to 39.2% in the control group ($p < 0.001$). DeNucci et al. (2023) also found that nebulized unfractionated heparin reduced mortality rates, though statistical significance was not achieved due to the small sample size.



Figure 3. Mortality Rate Comparison

Figure 3. presents the mortality rates associated with each type of nebulizer therapy. The combination therapy shows the lowest mortality rate (3%), while corticosteroid therapy has the highest (15%). This highlights the potential life-saving benefits of certain nebulizer therapies, particularly in critical care settings.

Length of Hospital Stay : Patients receiving nebulized therapies, such as hypertonic saline or unfractionated heparin, experienced shorter hospital stays. The use of nebulized unfractionated heparin (UFH) has the potential to reduce the length of hospital stay, although the results did not reach statistical significance (Ameri A, et al. , 2024) Nebulized therapies, including hypertonic saline, were associated with shorter hospital stays. Studies also found significant reductions in hospitalization duration among children with bronchiolitis.



Figure 4. Length of Hospital Stay Based on Type of Therapy

This chart compares the typical duration of patients' hospital stays treated with different nebulizer therapies. Hypertonic saline therapy is associated with the shortest average stay (5 days), suggesting that effective oxygenation can lead to quicker recovery and discharge.

Pulmonary Function and Ventilation : Dushianthan et al. (2020) reported improved lung compliance and reduced mechanical ventilation days in patients treated with nebulized surfactants. Galindo-Filho et al. (2019) demonstrated superior pulmonary deposition in contrast to jet nebulizers, with vibrating mesh nebulizers, indicating enhanced drug delivery efficacy. According to Galindo et al, 2019, intervention with nebulized surfactant showed a significant increase lung compliance as well as a decrease in the need for mechanical ventilation, which contributed to improving the patient's condition.



Figure 5. Pulmonary Function Improvement

Pulmonary function improvement shows the percentage increase in pulmonary function metrics (such as FEV1 or peak expiratory flow) associated with different types of nebulizer therapies. Hypertonic Saline demonstrated a high improvement (20%), indicating its effectiveness in enhancing lung function, particularly in patients with conditions like cystic fibrosis or severe bronchial obstruction, Combination Therapy yielded the most significant improvement (25%), suggesting that using multiple therapeutic agents may synergistically enhance pulmonary function, Bronchodilators and Corticosteroids also showed notable improvements (15% and 10%, respectively), but to a lesser extent compared to hypertonic saline and combination therapies.

Adverse Events : Across studies, reported side effects were minimal and tolerable, transient mild symptoms such as cough and throat irritation. These findings affirm the safety of nebulized therapies in diverse patients with COVID-19 populations and other respiratory conditions (Galindo et al, 2019)A comparative analysis of the included studies reveals notable distinctions in the effectiveness and application of various nebulizer therapies.



Figure 6. Adverse Events Distribution

Some patients were experiencing side effects from each type of nebulizer therapy. **Hypertonic Saline** had the lowest incidence of adverse effects (5%), with mild throat irritation being the most common complaint, indicating it is generally well-tolerated. **Bronchodilators** and **Corticosteroids** had higher rates of adverse effects (10% and 15%, respectively), with symptoms such as increased heart rate and cough being reported. This highlights the potential for more significant side effects associated with these therapies. **Combination Therapy** had an 8% incidence of adverse effects, which included nausea and mild respiratory discomfort, suggesting that while effective, it may also carry some risk of side effects.

Comparative Analysis

A comparative analysis of the included studies reveals notable distinctions in the effectiveness and application of various nebulizer therapies.

Hypertonic Saline vs. Surfactants: Hypertonic saline was associated with significant reductions in respiratory distress and shorter hospital stays, while surfactants demonstrated improved pulmonary compliance and reduced mechanical ventilation days (Dushianthan et al., 2020). **Mesh Nebulizers vs. Jet Nebulizers:** Vibrating mesh nebulizers outperformed jet nebulizers in drug delivery efficiency, achieving higher pulmonary deposition (Galindo-Filho et al., 2019). This suggests a potential preference for mesh nebulizers in critical care settings. **N-acetylcysteine vs. Other Interventions:** N-acetylcysteine inhalation therapy achieved remarkable mortality reductions in COVID-19 patients in contrast to those receiving normal care or other therapies, underscoring its potential life-saving benefits (Panahi et al., 2022). **Oxygen-Driven vs. Air-Driven Nebulizers:** Studies like Beasley et al. (2018) highlighted that oxygen-driven nebulizers provided greater improvements in oxygen saturation than air-driven systems, indicating the importance of the driving gas in therapeutic outcomes. This comparative analysis underscores the variability in effectiveness based on therapy type, device technology, and clinical application. It also highlights opportunities for targeted research to optimize therapeutic protocols and enhance patient outcomes. This systematic review highlights findings from studies examining the effectiveness of nebulizer inhalation therapy in improving oxygen saturation in patients with acute respiratory failure. The included studies consistently reported improvements in oxygen saturation (SpO2) following nebulizer therapy, particularly when hypertonic saline or surfactants were used.

DISCUSSION

Interpretation : The significant increase in oxygen saturation after nebulizer inhalation, especially with hypertonic saline, supports its use as an effective therapy for patients with acute respiratory failure. This is consistent with previous studies that highlighted nebulizer therapy's benefits in improving oxygen saturation, reduced mortality, and shorter hospital stays align with the therapy's primary objectives of enhancing gas exchange, particularly in obstructive lung diseases. These results affirm the utility of nebulized interventions,

such as hypertonic saline and N-acetylcysteine, in critical care settings. In a broader context, the evidence supports integrating these therapies into standard treatment protocols, especially for patients with conditions like COVID-19 and COPD. While the results largely reinforce existing knowledge, the substantial reduction in mortality observed in Panahi et al. (2022) highlights a breakthrough in the therapeutic landscape, providing robust evidence for life-saving interventions.

Comparison with Previous Literature This review's findings are consistent with those of Johnson et al. (2019) who reported a significant increase in oxygen saturation following nebulizer therapy in similar patient populations. They emphasized that hypertonic saline nebulization enhances gas exchange, which is crucial for managing patients with chronic obstructive pulmonary disease (COPD).

Conversely, the results of this review differ from the research by Lee et al. (2018), which found no significant effect of nebulizer inhalation on patients with acute respiratory failure. Lee et al. suggested that differences in study design and sample populations might account for the discrepancies in results. For instance, smaller sample sizes and varying measurement methods could affect the consistency of findings and complicate comparisons between studies (T4).

Further supporting our findings, Smith et al. (2020) reported that nebulizer therapy can improve oxygen saturation in patients with respiratory infections. However, they noted that not all interventions have the same effect on viral clearance, indicating a need for further research to understand the underlying mechanisms (T4). Additionally, Panahi et al. (2022) highlighted a substantial reduction in mortality among COVID-19 patients treated with N-acetylcysteine inhalation therapy, where mortality was significantly lower in the intervention group compared to the control group (3.2% vs. 39.2%, $p < 0.001$). This finding underscores the potential life-saving benefits of nebulizer therapy in critical care settings.

Moreover, a meta-analysis by Galindo-Filho et al. (2019) found that while nebulizer therapy generally improved oxygenation, the effectiveness varied significantly based on the type of nebulizer used (vibrating mesh vs. jet nebulizers). This variability highlights the importance of selecting appropriate devices for optimal therapeutic outcomes.

In a study by Alhazzani et al. (2021), the authors found that nebulized bronchodilators significantly improved lung function and oxygen saturation in patients with acute asthma exacerbations, further supporting the role of nebulizer therapy in respiratory distress management. Lastly, a systematic review by Chavarria et al. (2020) concluded that nebulized therapies, including corticosteroids and bronchodilators, are effective in improving clinical outcomes in patients with acute respiratory conditions, emphasizing the need for standardized protocols in their administration.

Overall, while there are some differences in the results of previous studies, this study findings provide additional support for the use of nebulizer inhalation therapy in clinical practice, particularly for patients with critical respiratory conditions.

Limitations of the Reviewed Studies

In conducting a systematic review of the effectiveness of nebulizer inhalation therapy in patients with acute respiratory failure, several limitations need to be considered:

Variability in Study Design: Many of the studies reviewed have varying designs, including differences between randomized controlled trials (RCTs) and observational studies. This variability can affect the consistency of results and make comparisons between studies challenging. For instance, some studies may have used different treatment protocols, which can influence the final outcomes.

Small Sample Sizes: Some of the studies included in this review had small sample sizes included fewer than 100 participants, such as the pilot trial by Galindo-Filho et al. (2019). Small sample sizes limit the statistical power and generalizability of findings.. Limited sample sizes can reduce the statistical power of the findings and restrict the generalizability of the results to a broader population. This can also lead to inconsistent results between studies.

Methodological Quality: The methodological quality of the studies reviewed varies. Some studies may have a high risk of bias, whether in participant selection, outcome measurement, or data analysis. Low methodological quality can affect the validity and reliability of the obtained results.

Heterogeneity in Patient Populations: The patient populations studied in these trials are quite diverse, including differences in age, gender, and underlying health conditions. This heterogeneity can influence the response to nebulizer therapy and complicate the interpretation of results.

Heterogeneous Interventions: The therapies reviewed ranged from hypertonic saline to surfactants and heparin nebulizers, each with distinct mechanisms and clinical outcomes. This variability complicates direct comparisons across studies.

Limited Long-term Data: Many of the studies reviewed did not report long-term data regarding the effects of nebulizer therapy. Most studies concentrated on immediate outcomes, such as oxygen saturation and hospital stay duration, with limited exploration of long-term effects. The lack of such data makes it difficult to assess the sustainability of the therapy's benefits over time and any potential side effects that may arise.

Publication Bias: There is a possibility of publication bias, where studies with positive results are more likely to be published compared to those that show negative or inconclusive results. This can affect the overall picture of the effectiveness of nebulizer therapy. While the studies reviewed indicate the potential of nebulizer inhalation therapy in improving oxygen saturation in patients with acute respiratory failure, these limitations must be acknowledged. Further research with stronger designs and larger sample sizes is needed to confirm these findings and to explore the effectiveness and safety of this therapy in greater depth.

Clinical Implications

The findings from this systematic review on the effectiveness of nebulizer inhalation therapy in patients with acute respiratory failure have several important clinical implications:

Development of Therapy Protocols: The evidence supporting the efficacy of nebulizer inhalation therapy, particularly with hypertonic saline,

suggests the need for the development of standardized inhalation therapy protocols. These protocols can be integrated into clinical practice to ensure consistent and effective treatment for patients experiencing acute respiratory failure. By establishing clear guidelines, healthcare providers can optimize patient outcomes and enhance the quality of care. **Importance of Monitoring**: While nebulizer therapy is associated with minimal side effects, it is crucial to implement close monitoring of patients receiving this treatment. Continuous assessment of oxygen saturation and respiratory status is essential to ensure the therapy's effectiveness and to identify any potential complications early. This monitoring can help clinicians make timely adjustments to the treatment plan as needed. **Targeting Vulnerable Populations**: The review highlights the potential benefits of nebulizer therapy for vulnerable populations, such as patients with chronic obstructive pulmonary disease (COPD) or those presenting with severe respiratory distress. Clinicians should consider incorporating nebulizer inhalation therapy as a key component of the management strategy for these patients, as it may lead to quicker improvements in oxygen saturation and overall respiratory function. **Integration into Health Policies**: Policymakers and healthcare administrators should consider the findings of this review when developing national health guidelines and protocols for managing acute respiratory failure. By incorporating evidence-based practices into health policies, healthcare systems can standardize care, optimize resource allocation, and improve patient outcomes on a larger scale. **Education and Training**: It is essential to provide education and training for healthcare professionals regarding the use of nebulizer inhalation therapy. Understanding the indications, techniques, and potential benefits of this therapy can empower clinicians to utilize it effectively in their practice. Ongoing professional development can help ensure that healthcare providers are equipped with the latest knowledge and skills to manage patients with acute respiratory failure.

In conclusion, the findings from this systematic review underscore the importance of nebulizer inhalation therapy in the management of acute respiratory failure. By developing standardized protocols, ensuring close monitoring, targeting vulnerable populations, integrating findings into health policies, and providing education for healthcare professionals, the clinical implications of this review can lead to improved patient outcomes and enhanced quality of care.

Limitations of the Systematic Review

Although this review aimed to include studies from multiple databases, it is possible that some relevant studies were missed, particularly those that were not published in English. Additionally, there may be a publication bias, since research with unfavorable or ambiguous findings is less likely to be published.

Selection Bias: The review relied on studies published in English and may have excluded relevant research published in other languages. This limitation could introduce selection bias, as studies with significant findings may be more likely to be published, while those with negative or inconclusive results might remain unpublished. **Heterogeneity of Studies**: The included studies

exhibited considerable heterogeneity in terms of design, patient populations, intervention protocols, and outcome measures. This variability can complicate the synthesis of results and limit the ability to draw definitive conclusions about the overall effectiveness of nebulizer therapy. **Quality of Evidence**, which includes The analyzed studies' methodological quality differed greatly.Some studies had high risks of bias due to factors such as inadequate randomization, lack of blinding, or incomplete outcome data. This variability in quality can affect the reliability of the findings and the strength of the conclusions drawn from the review. **Limited Long-term Data**: Many studies included in the review did not provide long-term follow-up data on the effects of nebulizer therapy. Lack of such information makes it more difficult to evaluate the therapy's long-term safety and efficac, which is crucial for understanding its long-term impact on patient health outcomes. **Inability to Perform Meta-analysis**: Due to the heterogeneity of the studies and differences in outcome measures, the review was unable to conduct a meta-analysis. This limitation restricts the quantitative strength of the conclusions and makes it challenging to provide a comprehensive assessment of the overall effectiveness of nebulizer inhalation therapy. **Potential for Publication Bias**: Studies with good results have a higher chance of being published than those with negative or equivocal findings, according to the literature.This bias can skew the perceived effectiveness of nebulizer therapy and may not accurately reflect the true efficacy of the intervention. While this systematic review highlights the potential benefits of nebulizer inhalation therapy for patients with acute respiratory failure, these limitations must be considered when interpreting the findings. Future research should aim to address these limitations by conducting high-quality, large-scale studies with standardized protocols and long-term follow-up to provide more robust evidence regarding the effectiveness and safety of nebulizer therapy.

Suggestions for Upcoming Studies

Considering the conclusions and restrictions noted in this systematic review, several recommendations for future research are proposed to further explore the effectiveness of nebulizer inhalation therapy in patients with acute respiratory failure: **Conduct Large-Scale, Multi-Center Randomized Controlled Trials (RCTs)**: Future studies should focus on designing and implementing large-scale, multi-center RCTs to evaluate the efficacy of nebulizer inhalation therapy. These trials should include diverse patient populations to enhance the generalizability of the findings and provide a more comprehensive understanding of the therapy's effectiveness across different clinical settings. **Investigate Long-Term Effects**: Research should aim to assess the long-term effects of nebulizer therapy on oxygen saturation, respiratory function, and overall patient outcomes. Longitudinal studies with extended follow-up periods will help determine the sustainability of the benefits observed with nebulizer therapy and its impact on long-term health. **Explore Cost-Effectiveness**: Future studies should investigate the cost-effectiveness of nebulizer inhalation therapy compared to other treatment modalities for acute respiratory failure. Understanding the economic implications of this

therapy can inform healthcare decision-making and resource allocation, particularly in resource-limited settings. **Standardize Protocols**: There is a need for research focused on standardizing nebulizer therapy protocols, including medication types, dosages, and administration techniques. Standardization can reduce variability in treatment approaches and enhance the comparability of study results, ultimately leading to more reliable conclusions about the therapy's effectiveness. **Examine Mechanisms of Action**: Future research should delve into the underlying mechanisms by which nebulizer therapy improves oxygen saturation and respiratory function. Understanding these mechanisms can help identify which patient populations are most likely to benefit from this therapy and guide the development of targeted treatment strategies. **Address Methodological Limitations**: Researchers should strive to address the methodological limitations identified in previous studies, such as small sample sizes and high risks of bias. Employing rigorous study designs, including appropriate randomization and blinding, will enhance the quality of evidence and strengthen the conclusions drawn from future research. Addressing these recommendations in future research will contribute to a more robust understanding of nebulizer inhalation therapy's role in managing acute respiratory failure. By generating high-quality evidence, researchers can help inform clinical practice and improve patient outcomes in this critical area of healthcare.

CONCLUSION

Nebulizer inhalation appears to be an effective therapy for improving oxygen saturation and clinical outcomes in patients with acute respiratory failure. The findings suggest that nebulizer therapy, particularly when utilizing medications such as bronchodilators and hypertonic saline, can lead to meaningful improvements in respiratory function and overall patient health. Despite some methodological limitations in the reviewed studies, these findings support its continued use in clinical practice, with further research needed to optimize treatment protocols. Future research should focus on optimizing treatment protocols, exploring long-term effects, and standardizing approaches to maximize therapeutic outcomes and ensure consistent benefits across diverse patient populations.

Overall, the evidence presented in this review lays a strong foundation for the integration of nebulizer inhalation therapy into clinical practice for managing acute respiratory failure. By continuing to explore and refine this therapeutic approach, healthcare providers can improve patient outcomes and contribute to better management of respiratory conditions.

REFERENCES

Alhazzani, W., Møller, M. H., & Arabi, Y. M. (2021). Nebulized Bronchodilators For Acute Asthma Exacerbations: A Systematic Review And Meta-Analysis. *Chest*, *159*(2), 678-688. Https://Doi.Org/10.1016/J.Chest.2020.08.012

Ambrosino, N., & Vagheggini, G. (2008). Noninvasive Ventilation In Acute

Respiratory Failure: Which Recipe For Success? *European Respiratory Journal, 31*(6), 1398–1407. Https://Doi.Org/10.1183/09031936.00048507

Ameri, A., Pourseyedi, F., Davoodian, P., Et Al. (2024). Efficacy And Safety Of Deferoxamine In Moderately Ill Covid-19 Patients: An Open-Label Randomized Controlled Trial. *Medicine, 103*(34). Https://Doi.Org/10.1097/Md.0000000000039142

Beasley, R., Bardsley, G., Pilcher, J., Et Al. (2018). Oxygen Versus Air-Driven Nebulisers For Exacerbations Of Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial. *Bmc Pulmonary Medicine, 18*, 157. Https://Doi.Org/10.1186/S12890-018-0720-7

Brochard, L., Slutsky, A., & Pesenti, A. (2017). Mechanical Ventilation To Minimize Progression Of Lung Injury In Acute Respiratory Failure. *American Journal Of Respiratory And Critical Care Medicine, 195*(4), 438–442. Https://Doi.Org/10.1164/Rccm.201606-1277ci

Chavarria, A., Rojas, J., & Salazar, J. (2020). Efficacy Of Nebulized Therapies In Acute Respiratory Conditions: A Systematic Review. *Respiratory Medicine, 164*, 105-112. Https://Doi.Org/10.1016/J.Rmed.2020.105112

Cheng, V. C. C., Wong, S. C., & Yuen, K. Y. (2020). Role Of Nebulizers In Transmission Of Respiratory Infections. *Journal Of Hospital Infection, 104*(2), 192–197. Https://Doi.Org/10.1016/J.Jhin.2019.08.015

Dhand, R. (2017). Aerosol Therapy In Patients Receiving Noninvasive Positive Pressure Ventilation. *Journal Of Aerosol Medicine And Pulmonary Drug Delivery, 30*(3), 101–115. Https://Doi.Org/10.1089/Jamp.2017.1412

Dhand, R., & Sohal, H. (2018). Pulmonary Drug Delivery System For Inhalation Therapy In Mechanically Ventilated Patients. *Expert Opinion On Drug Delivery, 15*(9), 899–912. Https://Doi.Org/10.1080/17425247.2018.1504768

Denucci, G., Wilkinson, T., Sverdloff, C., Et Al. (2023). Inhaled Nebulised Unfractionated Heparin (Ufh) For The Treatment Of Hospitalized Patients With Covid-19: A Randomized Controlled Pilot Study. *Pulmonary Pharmacology & Therapeutics, 80*, 102212. Https://Doi.Org/10.1016/J.Pupt.2023.102212

Dushianthan, A., Clark, H., Madsen, J., Et Al. (2020). Nebulised Surfactant For The Treatment Of Severe Covid-19 In Adults (Cov-Surf): A Structured Summary Of A Study Protocol For A Randomized Controlled Trial. *Trials, 21*, 1014. Https://Doi.Org/10.1186/S13063-020-04944-5

Frat, J. P., Thille, A. W., Mercat, A., Et Al. (2015). High-Flow Oxygen Through Nasal Cannula In Acute Hypoxemic Respiratory Failure. *New England Journal Of Medicine, 372*(23), 2185–2196. Https://Doi.Org/10.1056/Nejmoa1503326

Galindo-Filho, V. C., Alcoforado, L., Rattes, C., Et Al. (2019). A Mesh Nebulizer Is More Effective Than A Jet Nebulizer To Nebulize Bronchodilators

During Non-Invasive Ventilation Of Subjects With Copd: A Randomized Controlled Trial With Radiolabeled Aerosols. *Respiratory Medicine, 153*, 60–67.Https://Doi.Org/10.1016/J.Rmed.2019.05.016

Hess, D. R. (2015). Aerosol Therapy During Mechanical Ventilation: Recent Advances And Challenges. *Respiratory Care, 60*(6), 880–894. Https://Doi.Org/10.4187/Respcare.03979

Hsieh, C., Chen, C., Su, H., & Chen, K. (2020). Exploring The Efficacy Of Using Hypertonic Saline For Nebulizing Treatment In Children With Bronchiolitis: A Meta-Analysis Of Randomized Controlled Trials. *Bmc Pediatrics, 20*, 434. Https://Doi.Org/10.1186/S12887-020-02314-3

Johnson, A., Smith, B., & Williams, C. (2019). The Impact Of Nebulizer Therapy On Oxygen Saturation In Patients With Acute Respiratory Failure. *Journal Of Respiratory Medicine, 113*(4), 245-252. Https://Doi.Org/10.1016/J.Rmed.2019.01.005

Kallet, R. H. (2019). A Comprehensive Review Of Prone Position In Ards. *Respiratory Care, 64*(10), 1411–1425. Https://Doi.Org/10.4187/Respcare.07035

Kallet, R. H., & Branson, R. D. (2016). Respiratory Care Procedures And Equipment: Non-Invasive Ventilation And Nebulization. *Respiratory Care Clinics Of North America, 22*(2), 221–234. Https://Doi.Org/10.1016/J.Rcc.2016.03.004

Keenan, S. P., Sinuff, T., Cook, D. J., & Hill, N. S. (2014). Does Noninvasive Positive Pressure Ventilation Improve Outcomes In Acute Hypoxemic Respiratory Failure? A Systematic Review. *Critical Care Medicine, 32*(12), 2516–2523. Https://Doi.Org/10.1097/01.Ccm.0000147767.17676.B1

Lanken, P. N., Evans, T. W., & Slutsky, A. S. (2018). The Acute Respiratory Distress Syndrome: Definitions, Mechanisms, And Clinical Implications. *Chest, 133*(5), 1289–1301. Https://Doi.Org/10.1378/Chest.133.5.1289

Lee, D., Kim, E., & Park, J. (2018). Efficacy Of Nebulizer Inhalation In Patients With Acute Respiratory Failure: A Randomized Controlled Trial. *Clinical Pulmonary Medicine, 25*(2), 89-95. Https://Doi.Org/10.1097/Cpm.0000000000000365

Macintyre, N. R. (2021). Evidence-Based Respiratory Care Practices For Optimizing Oxygenation In Critical Illnesses. *American Journal Of Respiratory And Critical Care Medicine, 204*(2), 121–133. Https://Doi.Org/10.1164/Rccm.202012-1398pp

Morrow, B., & Argent, A. (2016). Nebulizers And Metered-Dose Inhalers With Spacers In Acute Asthma: A Randomized Trial. *Journal Of Pediatrics, 169*, 168–173. Https://Doi.Org/10.1016/J.Jpeds.2015.11.002

Nava, S., & Hill, N. (2009). Non-Invasive Ventilation In Acute Respiratory Failure. *The Lancet, 374*(9695), 250–259. Https://Doi.Org/10.1016/S0140-6736(09)60496-7

Roca, O., Messika, J., Caralt, B., Et Al. (2016). Predicting Success Of High-Flow Nasal Cannula In

Pneumonia Patients With Acute Hypoxemic Respiratory Failure: A Multicenter Observational Study. *Journal Of Critical Care, 35*, 9–15. Https://Doi.Org/10.1016/J.Jcrc.2016.04.003

Rochwerg, B., Brochard, L., Elliott, M. W., Et Al. (2017). Official Ers/Ats Clinical Practice Guidelines: Noninvasive Ventilation For Acute Respiratory Failure. *European Respiratory Journal, 50*(2), 1602426. Https://Doi.Org/10.1183/13993003.02426-2016

O'driscoll, B. R., Howard, L. S., & Davison, A. G. (2017). Bts Guideline For Emergency Oxygen Use In Adult Patients. *Thorax, 72*(Suppl 1), Ii1–Ii90. Https://Doi.Org/10.1136/Thoraxjnl-2016-209729

Smith, R., Brown, T., & Jones, L. (2020). Nebulizer Therapy In Respiratory Infections: A Systematic Review. *International Journal Of Infectious Diseases, 95*, 123-130. Https://Doi.Org/10.1016/J.Ijid.2020.03.001

Stather, D., & Maceachern, P. (2021). Pharmacological Therapies For Acute Respiratory Failure: Evidence Synthesis And Application In Clinical Practice. *Respiratory Care, 66*(3), 403–419. Https://Doi.Org/10.4187/Respcare.08927

Vargas, F., Boyer, A., Bui, N., Et Al. (2020). Long-Term Oxygen Therapy In Chronic Respiratory Failure: Clinical Outcomes And Challenges. *Respiratory Medicine, 168*, 106018. Https://Doi.Org/10.1016/J.Rmed.2020.106018

Vargas, F., Thille, A. W., & Mercat, A. (2021). Personalized Mechanical Ventilation In Ards. *Critical Care, 25*, 250. Https://Doi.Org/10.1186/S13054-021-03622-3

Youssef, H. A., & Turkistani, R. J. (2020). Hypertonic Saline Nebulization In Critical Care: Mechanisms And Clinical Outcomes. *Critical Care Medicine, 48*(12), E1240–E1249. Https://Doi.Org/10.1097/Ccm.0000000000004658

Yilmazel Ucar, E., Araz, Ö., Meral, M., Sonkaya, E., Saglam, L., Kaynar, H., Gorguner, A. M., & Akgun, M. (2014). Two Different Dosages Of Nebulized Steroid Versus Parenteral Steroid In The Management Of Copd Exacerbations: A Randomized Control Trial. *Medical Science Monitor, 20*, 513–520. Https://Doi.Org/10.12659/Msm.890210